Key facts
- This page summarizes Timothy DeVere Cook's Form 4 filing for Athenex, Inc..
- 1 reported transaction and 5 derivative rows are listed below.
- Accepted by SEC: 08 May 2023, 16:29.
Timothy DeVere Cook - 05 May 2023 Form 4 Insider Report for Athenex, Inc.
- Reporting relationship
- Chief Business and Commercial Officer, Proprietary Drugs
- Issuer ticker
- N/A
- Reported as of
- 05 May 2023
- Net transaction value
- +$500
- SEC form
- 4
- Accepted by SEC
- 08 May 2023, 16:29:48 UTC
- Prior SEC filing
- 24 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Steven Adams, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Timothy DeVere Cook filed Form 4 for Athenex, Inc. on 08 May 2023.
Change
- Previous filing in this sequence was filed on 24 Apr 2023.
- Current net transaction value: +$500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATNXQ
transaction
Common Stock
Award
- Transaction value
- $500
- Shares
- +368
- Change %
- +9.8%
- Price
- $1.36
- Shares after
- 4,140
- Date
- 05 May 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATNXQ
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,500
- Date
- 05 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,500
- Exercise price
- $345.80
ATNXQ
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,500
- Date
- 05 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,500
- Exercise price
- $205.20
- Footnotes
- F2
ATNXQ
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 450
- Date
- 05 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 450
- Exercise price
- $71.20
- Footnotes
- F3
ATNXQ
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 338
- Date
- 05 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 338
- Exercise price
- Footnotes
- F4, F5
ATNXQ
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,750
- Date
- 05 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,750
- Exercise price
- $13.31
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
Footnote F2
This option vests in four equal annual installments beginning on August 27, 2021.
Footnote F3
This option vests in four equal annual installments beginning on September 16, 2022.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of stock.
Footnote F5
The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
Footnote F6
This option vests in four equal annual installments beginning on July 20, 2023.
SEC remarks
Chief Business and Commercial Officer, Proprietary Drugs